Piek, Arnold <br/><br/>
Pharmacological myeloperoxidase (MPO) inhibition in an obese/hypertensive mouse model attenuates obesity and liver damage, but not cardiac remodeling.  [electronic resource] 

 -  Scientific reports  12 2019 
 - 18765 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-2322 
<br/><br/><label>Standard No.: </label>10.1038/s41598-019-55263-y  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiotensin II--administration & dosage<br/>Animals<br/>Diet, High-Fat--adverse effects<br/>Disease Models, Animal<br/>Heart Ventricles--drug effects<br/>Humans<br/>Hypertension--blood<br/>Hypertrophy, Left Ventricular--blood<br/>Intra-Abdominal Fat--drug effects<br/>Liver--drug effects<br/>Male<br/>Mice<br/>Non-alcoholic Fatty Liver Disease--blood<br/>Obesity--blood<br/>Peroxidase--antagonists & inhibitors<br/>Severity of Illness Index<br/>Thioxanthenes--administration & dosage<br/>Ventricular Remodeling--drug effects